Ta‐Chen Huang

P1.060. Long-Term Outcome of Adjuvant Chemoradiotherapy (CRT) Plus Pembrolizumab in Resectable Esophageal Squamous Cell Carcinoma (ESCC) at High Risk of Recurrence

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Adjuvant chemoradiotherapy followed by pembrolizumab (NCT03322267) has been shown to reduce relapses in patients at high risk of recurrence, including those with involved or close margins (≤1 mm), co...